Creative Touch Permanent Makeup and Aesthetics

GLP-1 receptor agonists do not recalibrate the body’s weight set point. They suppress appetite and alter satiety signalling pharmacologically – mechanisms that are active only while the drug is present. On withdrawal, the homeostatic pressure toward weight restoration reasserts itself against a caloric intake that is no longer constrained, and in a body whose resting energy expenditure has adapted downward during the loss phase. The result is predictable and well-quantified.

The STEP 1 trial extension followed 327 participants for 52 weeks after stopping semaglutide 2.4mg. After 17.3% mean weight loss during active treatment, participants regained 11.6 percentage points within one year – approximately 67% of their total weight loss reversed, with cardiometabolic improvements reverting toward baseline in parallel. ^[2] For tirzepatide, SURMOUNT-4 showed that participants who had achieved 20.9% weight loss during 36 weeks of treatment regained 14.0% within the following year on placebo. A post-hoc analysis of 308 participants found that 82.5% had regained at least 25% of their lost weight within 52 weeks of stopping, with 24% regaining 75% or more. ^[1] These figures establish cessation-related regain as the biological default, not an outlier outcome.

The Rebound Composition Problem

The aesthetics-critical insight is the compositional asymmetry between what was lost and what returns. During active GLP-1-mediated weight loss, approximately 25% of weight lost with tirzepatide and up to 40% with semaglutide comprised lean mass – skeletal muscle, bone density, and structural protein networks in skin and hair. When weight is regained after cessation, fat mass is restored preferentially and rapidly, driven by the same adipogenic and hormonal mechanisms defending the set point; lean mass restoration is slow, requires adequate protein intake and resistance training stimulus, and may not fully recover even at equivalent total body weight.

The skin consequence is specific: a client who returns to pre-treatment weight on the scale presents with more fat mass, less lean mass, reduced dermal collagen density from the depletion period, and an adipose inflammatory state – elevated IL-6, TNF-α, suppressed filaggrin expression – that is now reasserting itself against a dermis that was already structurally compromised by the rapid loss phase. This is the tissue correlate of the skin laxity and hair shedding that many clients describe after stopping GLP-1 medications, and it is mechanistically distinct from, and compounds, the laxity produced by the weight loss itself covered in the Rapid Weight Loss entity.

Hair Cycling and Weight Instability

Telogen effluvium typically resolves within three to six months of metabolic stabilisation following a single triggering event. Weight regain after GLP-1 cessation creates a second metabolic disruption – a period of caloric surplus, hormonal flux, and adipose inflammatory reassertion – that can trigger a further shift of follicles into telogen before the population has fully returned to a stable anagen baseline from the original loss-phase shedding. A client who sheds during active weight loss, partially recovers, then stops treatment and regains is potentially cycling through a second or third telogen disruption before follicular stability is re-established. In individuals with reduced follicular reserve – due to age, androgenetic alopecia, or prior nutritional depletion – this repeated cycling may produce more persistent thinning than any single episode would predict, as each cycle draws from a smaller remaining anagen population.

Sequencing Procedural Intervention

A client presenting during active regain – with adipose inflammation recovering, lean mass and collagen reserves still depleted, and potential ongoing follicular instability – is not in an optimal tissue environment for collagen-stimulating procedures. The sequencing logic favours: nutritional stabilisation and protein rehabilitation first; a settling period of three to six months post-regain stabilisation before major procedural intervention; and proactive follicular support initiated at the point of cessation, before shedding presents, rather than reactively after it does. Clients who maintain treatment continuity rather than stopping and restarting avoid the cyclical compositional damage of the cessation-regain pattern entirely – a clinical case for continuity that complements, rather than repeats, the metabolic argument made in the GLP-1 Receptor Agonists entity.